Scholar Rock (SRRK) Shares Soar over 320% on SMA Topline …
New York, October 07, 2024 - PRISM MarketView - The late-stage biopharmaceutical company Scholar Rock who focuses on treatments for spinal muscular atrophy (SMA), cardiometabolic …
OFF
Scholar Rock (SRRK) Shares Soar Over 320% On SMA Topline …
2 weeks from now
New York, October 07, 2024 - PRISM MarketView - The late-stage biopharmaceutical company Scholar Rock who focuses on treatments for spinal muscular atrophy (SMA), cardiometabolic …
prismmarketview.com
OFF
Scholar Rock Stock Surges On Positive Spinal Muscular Atrophy …
2 weeks from now
Oct 7, 2024 · Investing.com -- Shares of Scholar Rock Holdings skyrocketed 320% on Monday following the announcement of positive results from its Phase 3 SAPPHIRE clinical trial for …
yahoo.com
OFF
Scholar Rock Shares Soar 320% On Positive SMA Trial Results
2 weeks from now
Jan 24, 2025 · They underscored the pressing need for effective SMA treatments, reiterating a Buy rating for Scholar Rock and raising the price target from $20 to $36 per share. The …
thefinancialanalyst.net
OFF
Scholar Rock Stocks Skyrocket After SMA Drug Scores At Phase III
2 weeks from now
The company’s stock price rocketed by 362% after the news dropped, from a 4 October close of $7.42 to a close of $34.28 yesterday (7 October).
yahoo.com
OFF
SRRK Stock Soars As Muscle Disease Drug Meets Phase III Study Goal
2 weeks from now
Oct 8, 2024 · Shares of Scholar Rock SRRK skyrocketed 362% on Monday ... BHVN expects to report top-line data from the late-stage SMA study by the end of 2024. ... the full list has …
nasdaq.com
OFF
Scholar Rock (SRRK) Shares Soar Over 320% On SMA Topline …
2 weeks from now
Oct 7, 2024 · The late-stage biopharmaceutical company Scholar Rock who focuses on treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious …
prismmarketview.com
OFF
Phase 3 Scholar Rock Trial Hits SMA Goal, Sending Stock Up 200%
2 weeks from now
Oct 7, 2024 · In a pooled analysis of both doses, Scholar Rock saw a 1.8-point improvement in motor function over placebo after 52 weeks. The p-value was 0.0192. The result sent the …
fiercebiotech.com
OFF
Scholar Rock Reports Third Quarter 2024 Financial Results And ...
2 weeks from now
Nov 12, 2024 · Apitegromab is the first muscle-targeted therapy to show clinical proof-of-concept in SMA. Reported positive topline data ... share compared to a net loss of $42.4 million or …
morningstar.com
OFF
Scholar Rock Shares Target Increased, Holds Buy On SMA Drug …
2 weeks from now
Nov 25, 2024 · Monday, Truist Securities adjusted its outlook on Scholar Rock (NASDAQ:SRRK) shares, raising the biotechnology company's price target from $36.00 to $45.00 while …
investing.com
OFF
Scholar Rock's SMA Drug Hits Phase 3 Trial Goals; Secures $345M …
2 weeks from now
Nov 12, 2024 · Scholar Rock (SRRK) reported positive Phase 3 SAPPHIRE trial results for apitegromab in Spinal Muscular Atrophy (SMA), achieving its primary endpoint with statistically …
stocktitan.net
OFF
Scholar Rock’s Phase III Sapphire Gleams; Bright New Bid In SMA
2 weeks from now
Oct 7, 2024 · Shares of Scholar Rock Holding Corp. (NASDAQ:SRRK) soared $26.86, or 362%, to close Oct. 7 at $34.28, after the Cambridge, Mass.-based firm disclosed positive top-line …
bioworld.com
FAQs about Scholar Rock (SRRK) Shares Soar over 320% on SMA Topline … Coupon?
Why did Scholar Rock stock rise 320% on Monday?
Is scholar rock a good stock to buy if SMA is positive?
Why did scholar rock SRRK stock skyrocket 362% on Monday?
Should you buy scholar rock holding (SRRK) stock?
Is scholar rock a key target for spinal muscular atrophy (SMA)?
What does scholar rock do?
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
